In-depth guide

UPDATED FEB 2026

AFFF Kidney Cancer Lawsuit

Part of the AFFF Firefighting Foam investigation

The short answer

Kidney cancer (renal cell carcinoma) has the strongest scientific link to PFAS exposure of any cancer. IARC classified PFOA as a Group 1 carcinogen based largely on kidney cancer evidence.

Meta-analyses show a relative risk of 1.74 for kidney cancer at high PFAS exposure levels. The C8 Science Panel determined a "probable link" between PFOA and kidney cancer based on the 69,000-person Mid-Ohio Valley study. Firefighters and military personnel with kidney cancer and AFFF exposure history have among the strongest claims in MDL 2873.

People's Justice Research TeamUpdated February 20, 2026Fact-checked

Verified against court and regulatory records · No upfront fees · Your information is never sold

Free Case Review

Check your eligibility — free

Answer 2-3 quick questions to review your potential case.

Free · Confidential · About 2 minutes · A case specialist responds within 1 business day

Your answers are never sold or shared without your consent.

PFAS and Kidney Cancer: The Scientific Evidence

Kidney cancer — specifically renal cell carcinoma, which accounts for approximately 90% of kidney cancers — has the most extensively documented association with PFAS exposure of any malignancy. When the International Agency for Research on Cancer evaluated the carcinogenicity of PFOA in November 2023, the agency's working group classified PFOA as a Group 1 carcinogen — the highest classification — based primarily on the strength of evidence linking it to kidney cancer in humans.

The C8 Science Panel determined a "probable link" between PFOA exposure and kidney cancer after analyzing health data from 69,000 residents in the Mid-Ohio Valley. The panel found that individuals with higher PFOA blood levels had significantly elevated rates of kidney cancer diagnosis. Subsequent meta-analyses have quantified this risk, with Mastrantonio et al. (2023) finding a relative risk of 1.74 for kidney cancer among individuals with high PFAS exposure — meaning they are 74% more likely to develop kidney cancer than unexposed individuals.

The biological mechanism linking PFAS to kidney cancer involves several pathways. PFAS activate peroxisome proliferator-activated receptor alpha (PPARa), promoting cellular proliferation in the kidney. They generate oxidative stress that damages renal cell DNA and interfere with DNA repair mechanisms. PFAS also disrupt signaling pathways involved in cell growth regulation, including the VHL tumor suppressor pathway that is commonly mutated in renal cell carcinoma. These mechanisms are consistent with the epidemiological evidence and provide a biologically plausible explanation for the observed association.

Kidney Cancer Claims in the AFFF Litigation

Kidney cancer claims represent some of the highest-valued cases in MDL 2873 due to the strength of the causation science. Plaintiffs with kidney cancer who can document PFAS exposure — through firefighting employment records, military service records at contaminated bases, or residential history in contaminated communities — have a clear scientific basis for their claims supported by IARC Group 1 classification and C8 Science Panel "probable link" determination.

The C8 bellwether trials established the viability of kidney cancer claims against PFAS manufacturers. Carla Bartlett received a $1.6 million jury verdict in 2015 for kidney cancer caused by PFOA exposure from DuPont's Washington Works facility. This verdict — and the subsequent global settlement of approximately 3,550 C8 claims for $670.7 million — demonstrated that juries will hold manufacturers accountable for PFAS-linked kidney cancer.

Kidney cancer is often diagnosed at advanced stages because early-stage disease is frequently asymptomatic. For AFFF-exposed individuals, awareness of the PFAS-kidney cancer link is critical for early detection. Anyone with significant AFFF exposure should discuss enhanced kidney screening (including periodic CT scans or ultrasounds) with their healthcare provider, even in the absence of symptoms.

Research & evidence

Scientific Evidence

meta-analysis

Meta-Analysis of PFAS Exposure and Cancer Risk: Kidney and Testicular Cancer

Mastrantonio M, Bai E, Uccelli R, Cordiano V, Screpanti A, Corigliano P. (2023). La Medicina del Lavoro

Key findings

  • Relative risk of 1.74 for kidney cancer among individuals with high PFAS exposure compared to low-exposure controls
  • Relative risk of 2.22 for testicular cancer among individuals with high PFAS exposure — the strongest relative risk of any PFAS-cancer association
  • Dose-response relationship demonstrated: higher PFAS blood levels correlated with progressively higher cancer risk
  • Results consistent across multiple study designs and populations, strengthening the causal inference
retrospective

"The Devil They Knew": Industry Knowledge of PFAS Dangers Since 1970

Brennan NM, Evans AT, Fritz MK, Peak SA, von Holst HE. (2023). Annals of Global Health

Key findings

  • PFAS manufacturers knew about the persistence and toxicity of their products as early as 1970 — more than 50 years before widespread public awareness
  • 3M conducted internal studies showing PFAS bioaccumulation in worker blood at 1,000 times normal levels and animal studies showing tumor formation, then classified results as confidential
  • Manufacturers used trade secret protections and proprietary research agreements to prevent damaging findings from reaching regulators or the public
  • The pattern of corporate concealment parallels the tobacco and asbestos industries and supports punitive damages claims based on willful and malicious conduct
cohort

C8 Science Panel: Probable Link Evaluations for PFOA-Associated Diseases

Fletcher T, Savitz D, Steenland K. (2012). Environmental Health Perspectives

Key findings

  • Determined "probable link" between PFOA exposure and six diseases: kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, high cholesterol, and pregnancy-induced hypertension
  • Study population of 69,000 residents made it one of the largest PFAS health studies ever conducted, providing exceptional statistical power
  • Findings have been cited in virtually every subsequent PFAS lawsuit and regulatory action worldwide
  • The "probable link" standard — requiring more than just association but less than definitive proof — was a negotiated scientific threshold that has become the benchmark for PFAS causation evidence

FAQ

Frequently Asked Questions

36 QUESTIONS

The primary categories of eligible plaintiffs include: firefighters (municipal, airport, military, or industrial) who handled AFFF during training or fire suppression; military personnel stationed at bases where AFFF was used or stored (the DoD has identified 455+ contaminated installations); military families who lived on or near contaminated bases; community residents whose drinking water was contaminated by PFAS from nearby military bases, airports, or fire training facilities; and industrial workers at PFAS manufacturing plants. Linked conditions include kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, liver damage, non-Hodgkin lymphoma, and high cholesterol. Attorneys handle these cases on contingency — fee terms vary by attorney.

Dive deeper

Related Guides

7 GUIDES

The full investigation

Part of the AFFF Firefighting Foam Investigation